| Clinical Symptom | Documentation Expectation | Coding Impact |
|---|---|---|
| Dyspnea on exertion | Record exertional limitation and trigger activity level. | Supports chronic HFrEF (I50.22) as defined by AHA/ACC guidelines. |
| Orthopnea or paroxysmal nocturnal dyspnea | Note positional worsening of breathing during rest or sleep. | Indicates pulmonary congestion consistent with I50.21 or I50.23 (acute or acute on chronic). |
| Peripheral edema | Document severity, duration, and response to therapy. | Correlates with volume overload that justifies IV diuretic therapy under CMS coverage rules. |
| Fatigue and reduced exercise tolerance | Quantify in NYHA functional classes I-IV. | Links directly to severity coding and risk adjustment validation. |
| Rapid weight gain / fluid retention | Include daily weight monitoring details. | Reinforces disease progression, often triggers repeat echo orders (CPT 93306). |
| ICD-10 Code | Description | Documentation Requirement |
|---|---|---|
| I50.20 | Unspecified systolic heart failure | Use only when acuity (acute/chronic) is not documented. Avoid when EF and timeframe are known, as this may trigger specificity edits per CMS guidelines. |
| I50.21 | Acute systolic heart failure | Requires evidence of sudden decompensation; document symptoms such as pulmonary edema, orthopnea, or hospitalization for IV diuretics as per AHA standards. |
| I50.22 | Chronic systolic heart failure | Use when HFrEF is stable and the patient is maintained on guideline-directed medical therapy (GDMT). EF ≤ 40% should be clearly stated in the medical record. |
| I50.23 | Acute on chronic systolic heart failure | Used when a chronic patient experiences acute exacerbation. Documentation must specify baseline EF, current decompensation signs, and treatment response. |
| ICD-10 Chapter | Code Range | HFrEF Placement | Sequencing Guideline |
|---|---|---|---|
| Chapter IX: Diseases of the Circulatory System | I00–I99 | I50.2x – Systolic (HFrEF) | Code the underlying cause first (e.g., hypertension, ischemic disease), followed by I50.2x per CMS sequencing rules. |
| Chapter I: Certain Infectious and Parasitic Diseases | A00–B99 | Rarely used in HF coding | Use if heart failure is secondary to myocarditis due to infection, sequenced after infectious agent code. |
| Chapter XX: External Causes of Morbidity | V00–Y99 | Not applicable to HFrEF | Use only if external trauma causes cardiac injury leading to failure. |
| CPT Code | Procedure Description | Documentation Requirement |
|---|---|---|
| 93306 | Complete transthoracic echocardiography with Doppler and color flow study | Must include EF measurement, ventricular function, and interpretation. Required for confirming HFrEF (EF ≤ 40%) per AHA/ACC guidelines. |
| 93000 | Electrocardiogram (ECG) with interpretation | Record rhythm and conduction findings linked to HFrEF management (e.g., LBBB, atrial fibrillation). |
| 83880 | B-type natriuretic peptide (BNP or NT-proBNP) assay | Document reason for test: differentiating dyspnea causes or monitoring HFrEF decompensation per CMS LCD policies. |
| 33249 | Insertion or replacement of transvenous ICD with defibrillation capability | EF ≤ 35% after ≥3 months of GDMT; justification must reference 2026 AHA/ACC/HFSA criteria. |
| 33225 | LV lead placement for cardiac resynchronization therapy (CRT-D) | Link to “LBBB with EF ≤ 35%, NYHA class II–IV,” per clinical guideline documentation. |
| 99490 | Chronic care management, ≥20 minutes per month | Provider must document longitudinal management of chronic HFrEF and care coordination efforts, per CMS CCM program. |
| Treatment Category | Typical Clinical Documentation | Coding and Billing Consideration |
|---|---|---|
| ARNI/ACEI/ARB Therapy | “Started on sacubitril/valsartan per GDMT for HFrEF, EF 35%” | Confirms EF ≤ 40% and guideline adherence, strengthens claim linkage with I50.22 (chronic HFrEF). |
| Beta-Blocker and MRA Therapy | “Continuing carvedilol and spironolactone with stable symptoms” | Supports chronic management and continuity of care billing (CPT 99490). |
| SGLT2 Inhibitors | “Initiated dapagliflozin as add-on for HFrEF symptom control” | Justifies prescription under heart failure coverage policy per CMS Part D guidance. |
| Device Therapy (ICD/CRT-D) | “Meets criteria for CRT-D: EF 30%, LBBB, NYHA Class III” | Documented under I50.23 with CPT 33249 + 33225 for device implantation. |
| Echocardiography Follow-Up | “Repeat echo ordered to evaluate EF improvement post-therapy” | CPT 93306 linked to I50.22 to confirm ongoing HFrEF monitoring. |
| Acute Decompensation Management | “Admitted with acute on chronic HFrEF, IV diuretics, and oxygen therapy” | Supports acute coding (I50.23) with CPT 99223–99233 for inpatient E/M services. |
| Documentation Gap | Denial Trigger (with source) | Corrective Strategy (with reference) |
|---|---|---|
| Missing EF data | Claims fail coverage under the CMS LCD L34356 for heart failure diagnostics because EF confirmation is absent. | Include “EF ≤ 40% confirmed by echo” per AHA/ACC Heart Failure Guidelines 2022. |
| Generic “CHF” without subtype | Use of I50.9 violates specificity standards in the ICD-10-CM Official Guidelines FY 2026. | Document and code explicitly as HFrEF or systolic heart failure (I50.2x) with acuity, following AHIMA documentation best practices. |
| CPT not linked to ICD-10 | Procedures like 93306 or 33249 fail medical-necessity validation under CMS NCD Manual §20.33. | Link all cardiology procedures to the corresponding I50.2x code, verifying pairings via the CMS NCCI Edit Table. |
| No documentation of treatment response | Post-payment reviews under the OIG Work Plan FY 2026 cite “lack of follow-up outcome data.” | Record EF trends and GDMT response per HFMA Revenue Integrity Report 2026. |
| Incomplete admission context | DRG downgraded for “unspecified acute episode” during inpatient review per CMS MS-DRG Definitions Manual 2024. | State: “Admitted for acute on chronic HFrEF requiring IV diuretics,” aligning with AHA inpatient coding guidance. |
